859 related articles for article (PubMed ID: 26749141)
21. First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography-guided biopsies for the diagnosis of localised prostate cancer.
Mozer P; Rouprêt M; Le Cossec C; Granger B; Comperat E; de Gorski A; Cussenot O; Renard-Penna R
BJU Int; 2015 Jan; 115(1):50-7. PubMed ID: 24552477
[TBL] [Abstract][Full Text] [Related]
22. Identification of threshold prostate specific antigen levels to optimize the detection of clinically significant prostate cancer by magnetic resonance imaging/ultrasound fusion guided biopsy.
Shakir NA; George AK; Siddiqui MM; Rothwax JT; Rais-Bahrami S; Stamatakis L; Su D; Okoro C; Raskolnikov D; Walton-Diaz A; Simon R; Turkbey B; Choyke PL; Merino MJ; Wood BJ; Pinto PA
J Urol; 2014 Dec; 192(6):1642-8. PubMed ID: 25117476
[TBL] [Abstract][Full Text] [Related]
23. Optimizing the Number of Cores Targeted During Prostate Magnetic Resonance Imaging Fusion Target Biopsy.
Kenigsberg AP; Renson A; Rosenkrantz AB; Huang R; Wysock JS; Taneja SS; Bjurlin MA
Eur Urol Oncol; 2018 Oct; 1(5):418-425. PubMed ID: 31158081
[TBL] [Abstract][Full Text] [Related]
24. MRI/US fusion-guided prostate biopsy allows for equivalent cancer detection with significantly fewer needle cores in biopsy-naive men.
Yarlagadda VK; Lai WS; Gordetsky JB; Porter KK; Nix JW; Thomas JV; Rais-Bahrami S
Diagn Interv Radiol; 2018; 24(3):115-120. PubMed ID: 29770762
[TBL] [Abstract][Full Text] [Related]
25. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
[TBL] [Abstract][Full Text] [Related]
26. A prospective, blinded comparison of magnetic resonance (MR) imaging-ultrasound fusion and visual estimation in the performance of MR-targeted prostate biopsy: the PROFUS trial.
Wysock JS; Rosenkrantz AB; Huang WC; Stifelman MD; Lepor H; Deng FM; Melamed J; Taneja SS
Eur Urol; 2014 Aug; 66(2):343-51. PubMed ID: 24262102
[TBL] [Abstract][Full Text] [Related]
27. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy.
Siddiqui MM; Rais-Bahrami S; Truong H; Stamatakis L; Vourganti S; Nix J; Hoang AN; Walton-Diaz A; Shuch B; Weintraub M; Kruecker J; Amalou H; Turkbey B; Merino MJ; Choyke PL; Wood BJ; Pinto PA
Eur Urol; 2013 Nov; 64(5):713-719. PubMed ID: 23787357
[TBL] [Abstract][Full Text] [Related]
28. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance.
Tran GN; Leapman MS; Nguyen HG; Cowan JE; Shinohara K; Westphalen AC; Carroll PR
Eur Urol; 2017 Aug; 72(2):275-281. PubMed ID: 27595378
[TBL] [Abstract][Full Text] [Related]
29. Multiparametric magnetic resonance imaging for prostate cancer improves Gleason score assessment in favorable risk prostate cancer.
Kamrava M; Kishan AU; Margolis DJ; Huang J; Dorey F; Lieu P; Kupelian PA; Marks LS
Pract Radiat Oncol; 2015; 5(6):411-6. PubMed ID: 26059510
[TBL] [Abstract][Full Text] [Related]
30. Comparison of systematic transrectal biopsy to transperineal magnetic resonance imaging/ultrasound-fusion biopsy for the diagnosis of prostate cancer.
Borkowetz A; Platzek I; Toma M; Laniado M; Baretton G; Froehner M; Koch R; Wirth M; Zastrow S
BJU Int; 2015 Dec; 116(6):873-9. PubMed ID: 25523210
[TBL] [Abstract][Full Text] [Related]
31. Are Magnetic Resonance Imaging-Transrectal Ultrasound Guided Targeted Biopsies Noninferior to Transrectal Ultrasound Guided Systematic Biopsies for the Detection of Prostate Cancer?
Delongchamps NB; Portalez D; Bruguière E; Rouvière O; Malavaud B; Mozer P; Fiard G; Cornud F;
J Urol; 2016 Oct; 196(4):1069-75. PubMed ID: 27079582
[TBL] [Abstract][Full Text] [Related]
32. Comparative Effectiveness of Targeted Prostate Biopsy Using Magnetic Resonance Imaging Ultrasound Fusion Software and Visual Targeting: a Prospective Study.
Lee DJ; Recabal P; Sjoberg DD; Thong A; Lee JK; Eastham JA; Scardino PT; Vargas HA; Coleman J; Ehdaie B
J Urol; 2016 Sep; 196(3):697-702. PubMed ID: 27038768
[TBL] [Abstract][Full Text] [Related]
33. Systematic prostate biopsy still matters: A comprehensive analysis of MRI/TRUS-fusion targeted prostate biopsies across different indications.
Westhoff N; Baeßler B; von Hardenberg J; Hetjens S; Porubsky S; Siegel F; Martini T; Michel MS; Attenberger U; Ritter M
Urol Oncol; 2019 Oct; 37(10):678-687. PubMed ID: 31375340
[TBL] [Abstract][Full Text] [Related]
34. Reducing the demand for magnetic resonance imaging scans and prostate biopsies during the early detection of clinically significant prostate cancer: Applying the Barcelona risk-stratified pathway in Catalonia.
Morote J; Borque-Fernando Á; Esteban LE; Picola N; Muñoz-Rodriguez J; Paesano N; Ruiz-Plazas X; Muñoz-Rivero MV; Celma A; García-de Manuel G; Miró B; Abascal JM; Servian P
Urol Oncol; 2024 Apr; 42(4):115.e1-115.e7. PubMed ID: 38342654
[TBL] [Abstract][Full Text] [Related]
35. Limitations of overlapping cores in systematic and MRI-US fusion biopsy.
Lee AY; Yang XY; Lee HJ; Law YM; Huang HH; Sim AS; Lau WK; Lee LS; Cheng CW; Ho HS; Yuen JS; Tay KJ; Chen K
Urol Oncol; 2021 Nov; 39(11):782.e15-782.e21. PubMed ID: 33888423
[TBL] [Abstract][Full Text] [Related]
36. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer.
Siddiqui MM; Rais-Bahrami S; Turkbey B; George AK; Rothwax J; Shakir N; Okoro C; Raskolnikov D; Parnes HL; Linehan WM; Merino MJ; Simon RM; Choyke PL; Wood BJ; Pinto PA
JAMA; 2015 Jan; 313(4):390-7. PubMed ID: 25626035
[TBL] [Abstract][Full Text] [Related]
37. The ultrasound characteristics of regions identified as suspicious by magnetic resonance imaging (MRI) predict the likelihood of clinically significant cancer on MRI-ultrasound fusion-targeted biopsy.
Press B; Rosenkrantz AB; Huang R; Taneja SS
BJU Int; 2019 Mar; 123(3):439-446. PubMed ID: 30415476
[TBL] [Abstract][Full Text] [Related]
38. Clinical utility of MR/ultrasound fusion-guided biopsy in patients with lower suspicion lesions on active surveillance for low-risk prostate cancer.
Lokeshwar SD; Nguyen J; Rahman SN; Khajir G; Ho R; Ghabili K; Leapman MS; Weinreb JC; Sprenkle PC
Urol Oncol; 2022 Sep; 40(9):407.e21-407.e27. PubMed ID: 35811206
[TBL] [Abstract][Full Text] [Related]
39. The utility of in-bore multiparametric magnetic resonance-guided biopsy in men with negative multiparametric magnetic resonance-ultrasound software-based fusion targeted biopsy.
Perrin A; Venderink W; Patak MA; Möckel C; Fehr JL; Jichlinski P; Porcellini B; Lucca I; Futterer J; Valerio M
Urol Oncol; 2021 May; 39(5):297.e9-297.e16. PubMed ID: 33341358
[TBL] [Abstract][Full Text] [Related]
40. An initial negative round of targeted biopsies in men with highly suspicious multiparametric magnetic resonance findings does not exclude clinically significant prostate cancer-Preliminary experience.
Costa DN; Kay FU; Pedrosa I; Kolski L; Lotan Y; Roehrborn CG; Hornberger B; Xi Y; Francis F; Rofsky NM
Urol Oncol; 2017 Apr; 35(4):149.e15-149.e21. PubMed ID: 27939349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
